hitting a plateau on semaglutide Breaking Plateaus: How Works When Diet and Exercise Aren't – Calibrate IV Breaking a Weight-Loss Plateau with

Like other incretin-based medications, the most common side effects were gastrointestinal: Common Side Effects Nausea: Reported in approximately 25-45% of participants depending on dose (most common during titration) Diarrhea: Approximately 20-35% of participants Vomiting: Approximately 10-20% of participants Constipation: Approximately 10-15% of participants Decreased appetite: Common and expected given the mechanism of action Less Common but Notable Effects Increased heart rate: Small elevations in resting heart rate were observed, consistent with other GLP-1 class medications Injection site reactions: Mild redness or itching at injection sites Fatigue: Reported by some participants, particularly during dose escalation Most adverse events were mild to moderate and occurred primarily during the dose escalation phase

Patients initiating GLP-1 therapy for diabetes or weight management who also experience joint pain should maintain a comprehensive approach to musculoskeletal health

Many patients report significant improvement or complete resolution of nausea and related symptoms within 23 months of maintaining a stable dose

Available at: [Last accessed January 18, 2024]

GLP-1 15 Glucagon-like peptide-1 (GLP-1) 2014 4

Stay Well Hydrated: Drink plenty of water to prevent constipation, a potential side effect of GLP-1